Search results
Vanda Pharmaceuticals Receives Another Takeover Proposal, Considers $466M Deal - Vanda Pharma...
Benzinga· 2 hours agoIn May, Cycle launched its sixth drug product in the U.S. market. In April, Vanda rejected Future Pak LLC’s proposal of $7.25 – $7.75 per share, saying it significantly undervalued the company ...
Amphastar Announces Additional $50 Million Increase to its Share Buyback Program
Morningstar· 2 days agoRANCHO CUCAMONGA, CA / ACCESSWIRE / June 4, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) today announced that on June 3, 2024, the Company's Board...ANDAs") on file ...
Why Is Rocket Pharmaceuticals (RCKT) Down 4.8% Since Last Earnings Report?
Zacks via Yahoo Finance· 1 day agoWill the recent negative trend continue leading up to its next earnings release, or is Rocket ...
Ani Pharmaceuticals CFO sells shares worth over $317k By Investing.com
Investing.com· 7 hours agoANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has reported a significant transaction involving its Senior...
Cheaper Ozempic Alternatives Are Out There. Be Wary of Fakes and Fraudsters.
The Wall Street Journal· 5 hours agoMillions of people are taking Ozempic, Wegovy or Mounjaro for weight loss. Compounded drugs are...
FDA Declines Approval Of MDMA As Treatment For PTSD
International Business Times· 22 hours agoThe Food and Drug Administration has declined to recommend approval for the use of MDMA, more popularly known as molly or ecstasy, to treat...
Vanda Pharmaceuticals Announces Completion of Transfer of FDA Marketing Authorization for PONVORY®
The Pilot News· 7 days agoVanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that ownership of the U.S. New Drug ...Company, which now fully allows Vanda to commercialize PONVORY® in ...
MDMA-Maker Failed Its FDA Hearing — And Its PTSD Patients
Bloomberg· 1 day agoLykos Therapeutics showed up to a regulatory hearing woefully unprepared. Lisa Jarvis is a Bloomberg...
FDA approves Moderna’s RSV vaccine mRESVIA
Pharmaceutical Technology via Yahoo Finance· 3 days agoIn 2023, Moderna agreed to establish an mRNA manufacturing facility in Kenya. The new advanced facility will have the capacity to produce up to 500...
Jazz Pharmaceuticals stock maintains Outperform rating By Investing.com
Investing.com· 7 hours agoOn Thursday, RBC (TSX:RY) Capital Markets sustained its Outperform rating and $176.00 price target...